Evidence map›Paper›PMID 42093471›Full record

ArticleOncoimmunology2026

Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.

Jessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, Mari F C M van den Hout, Vinitha Kandiah, Mariette Labots, Rieneke van de Ven, Alfons J M van den Eertwegh, Tanja D de Gruijl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica C L NotohardjoDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.ORCID 0000-0001-8199-6169
Elisa C ToffoliDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Tara MuijlwijkCancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Mari F C M van den HoutDepartment of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, Maastricht, The Netherlands.
Vinitha KandiahDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Mariette LabotsDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Rieneke van de VenCancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Alfons J M van den EertweghDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Tanja D de GruijlDepartment of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.ORCID 0000-0003-1464-8978

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher

Indexed as

MelanomaSentinel Lymph NodeSkin NeoplasmsToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptor 9AminoquinolinesCytokinesDendritic CellsFemaleHumansImidazolesMaleNeoplasm StagingOligodeoxyribonucleotidesSentinel Lymph Node BiopsyAminoquinolinesCytokinesImidazolesOligodeoxyribonucleotidesProMuneresiquimodTLR7 protein, humanTLR8 protein, humanTLR9 protein, humanToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptor 9Toll-Like Receptor AgonistsDendritic cellmelanomasentinel lymph nodesex differenceTLR ligands

Identifiers

PMID42093471
PMCPMC13166185

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.